BeyondSpring (Nasdaq:BYSI) - Hisse Senedi Fiyatı, Haberler ve Analizler

BYSI Stoklara Genel Bakış

Klinik aşamada bir biyofarmasötik şirketi olan BeyondSpring Inc. iştirakleriyle birlikte kanser tedavilerinin geliştirilmesine odaklanmaktadır. Daha fazla detay

BYSI temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	1/6
Temettüler	0/6

Ödüller

Kazançlar son 5 yılda yılda 15.4% oranında arttı

Risk Analizi

Negatif hissedar öz sermayesi

Anlamlı bir geliri yok ( $2M )

Hissedarlar geçen yıl sulandırıldı

Anlamlı bir piyasa değeri yok ( $69M )

BeyondSpring Inc. Rakipler

Aligos Therapeutics

NasdaqCM:ALGS

US$67.6m

Atara Biotherapeutics

NasdaqGS:ATRA

US$60.6m

Sorrento Therapeutics

OTCPK:SRNE.Q

US$60.4m

Celularity

NasdaqCM:CELU

US$64.7m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti BeyondSpring
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$1.74
52 Haftanın En Yüksek Seviyesi	US$4.00
52 Haftanın En Düşük Seviyesi	US$0.78
Beta	0.30
11 Aylık Değişim	-21.38%
3 Aylık Değişim	-9.38%
1 Yıllık Değişim	91.21%
33 Yıllık Değişim	-86.90%
5 Yıllık Değişim	-86.63%
Halka arzdan bu yana değişim	-89.64%

Son Haberler & Güncellemeler

Recent updates

BeyondSpring: Poor Trial Conduct And Lack Of Transparency Create Substantial Downside Risk

Sep 07

BeyondSpring's Plinabulin: Upcoming PDUFA And Positioning In The CIN Space

Aug 01

BeyondSpring EPS misses by $0.04

Jun 16

BeyondSpring reports positive plinabulin combo data for prevention of chemotherapy-induced neutropenia

Jun 07

FDA grants accelerated review to BeyondSpring's plinabulin combo application; shares up 8%

Jun 01

BeyondSpring EPS misses by $0.17

Apr 30

How Much Of BeyondSpring Inc. (NASDAQ:BYSI) Do Insiders Own?

Dec 22

BeyondSpring: Would Be A Great Buy Except For The Perennial Need For Cash And Ensuing Dilution

Dec 15

BeyondSpring slides 9% on public offering pricing at $10.0/share

Nov 19

BeyondSpring under pressure on shares offering

Nov 17

BeyondSpring's plinabulin combo meets primary endpoint in neutropenia trial

Nov 16

Hissedar Getirileri

	BYSI	US Biotechs	US Pazar
7D	0.8%	-3.7%	0.3%
1Y	91.2%	15.2%	31.1%

Getiri vs. Endüstri: BYSI geçen yıl % 15.2 oranında getiri sağlayan US Biotechs sektörünü aştı.

Getiri vs Piyasa: BYSI geçen yıl % 31.1 oranında getiri sağlayan US Piyasasını aştı.

Fiyat Oynaklığı

Is BYSI's price volatile compared to industry and market?
BYSI volatility
BYSI Average Weekly Movement	8.0%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: BYSI son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: BYSI 'nin haftalık oynaklığı geçtiğimiz yıl boyunca 16% dan 8% a düştü.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2010	36	Lan Huang	beyondspringpharma.com

Klinik aşamada bir biyofarmasötik şirketi olan BeyondSpring Inc. iştirakleriyle birlikte kanser tedavilerinin geliştirilmesine odaklanmaktadır. Şirketin öncü varlığı, küçük hücreli dışı akciğer kanseri (NSCLC) tedavisi için Faz III klinik çalışmalarını tamamlayan seçici bir immünomodüle edici mikrotübül bağlayıcı ajan olan Plinabulin'dir; ve kemoterapiye bağlı nötropeninin önlenmesinin yanı sıra bir anti-kanser ajanı olarak. Ayrıca Plinabulin'i, KHDAK ve epidermal büyüme faktörü reseptörü vahşi tip tedavisi için tek başına dosetaksele karşı dosetaksel ile kombinasyon halinde geliştirmektedir.

BeyondSpring Inc. Temel Bilgiler Özeti

BeyondSpring'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
BYSI temel i̇stati̇sti̇kler
Piyasa değeri	US$68.91m
Kazançlar(TTM)	-US$15.57m
Gelir(TTM)	US$1.88m

37.4x

P/S Oranı

-4.5x

F/K Oranı

BYSI aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
BYSI gelir tablosu (TTM)
Gelir	US$1.88m
Gelir Maliyeti	US$0
Brüt Kâr	US$1.88m
Diğer Giderler	US$17.44m
Kazançlar	-US$15.57m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.39
Brüt Marj	100.00%
Net Kâr Marjı	-829.85%
Borç/Özkaynak Oranı	0%

BYSI uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

BYSI Stoklara Genel Bakış

Ödüller

Risk Analizi

BeyondSpring Inc. Rakipler

NasdaqCM:ALGS

US$67.6m

NasdaqGS:ATRA

US$60.6m

OTCPK:SRNE.Q

US$60.4m

NasdaqCM:CELU

US$64.7m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting

BeyondSpring Inc. Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-Type NSCLC at NSCLC Congress 2024

First half 2024 earnings released: US$0.19 loss per share (vs US$0.33 loss in 1H 2023)

New minor risk - Shareholder dilution

New minor risk - Market cap size

BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price Rule

Recent updates

BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting

BeyondSpring Inc. Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-Type NSCLC at NSCLC Congress 2024

First half 2024 earnings released: US$0.19 loss per share (vs US$0.33 loss in 1H 2023)

New minor risk - Shareholder dilution

New minor risk - Market cap size

BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price Rule

First half 2023 earnings released: US$0.33 loss per share (vs US$0.47 loss in 1H 2022)

New major risk - Revenue and earnings growth

BeyondSpring Inc. Announces New Data That Translates Preclinical Proof-Of-Concept to Clinical Evidence of Plinabulin’s Immunomodulating Activity

New minor risk - Financial data availability

BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price Requirement

New major risk - Share price stability

BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements

BeyondSpring Inc. Announces Retirement of Yanbin Xie as Board of Director

Here's Why We're Watching BeyondSpring's (NASDAQ:BYSI) Cash Burn Situation

BeyondSpring Inc. Announces New Data from Phase 1 Investigator Initiated Study Plinabulin’s Ability to Reduce Infectious Neutropenic Fever for Multiple Myeloma Patients Undergoing AHCT

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

BeyondSpring Receives Notifications from Nasdaq Regarding Compliance With Listing Rules

BeyondSpring Inc. Announces the Resignation of Christine Ying Zhao from the Board of Directors, Effective January 1, 2023

BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements

Price target decreased to US$2.30

BeyondSpring Inc. Presents New Clinical Evidence of Plinabulin Protection of Granulocyte-Monocyte Progenitor Stem Cells for the Prevention of Chemotherapy-Induced Neutropenia at the ESMO Congress 2022

BeyondSpring Inc. Announces Board Appointments

BeyondSpring Inc.(NasdaqCM:BYSI) dropped from Russell 2000 Dynamic Index

BeyondSpring Inc. Announces Executive Resignations, with Effect from June 9, 2022

BeyondSpring Inc. Announces Resignation of Gordon L. Schooley as Chief Regulatory Officer

Price target decreased to US$6.10

Elizabeth Czerepak Resigns as Executive Vice President of BeyondSpring Inc

Consensus forecasts updated

Price target increased to US$13.67

BeyondSpring Inc. to Report Q4, 2021 Results on Apr 14, 2022

BeyondSpring, Beyond Salvage

BeyondSpring Pharmaceuticals Announces Organizational Streamlining

Consensus revenue estimates fall by 90%

BeyondSpring Pharmaceuticals Announces New Clinical Data Confirming Plinabulin’s Fast Onset Mechanism of Action in Prevention of Chemotherapy-Induced Neutropenia at 63rd ASH Annual Meeting and Exposition

Consensus forecasts updated

BeyondSpring Pharmaceuticals Receives Complete Response Letter from the FDA for Plinabulin New Drug Application for Prevention of Chemotherapy-Induced Neutropenia (CIN)

No longer forecast to breakeven

Circling Back On BeyondSpring

Price target decreased to US$58.60

Upcoming News For BeyondSpring's Plinabulin Tees Up Big Potential Returns

BeyondSpring: Poor Trial Conduct And Lack Of Transparency Create Substantial Downside Risk

Price target increased to US$67.25

BeyondSpring's Plinabulin: Upcoming PDUFA And Positioning In The CIN Space

Consensus forecasts updated

BeyondSpring Inc.(NasdaqCM:BYSI) dropped from Russell Microcap Value Index

Consensus forecasts updated

BeyondSpring EPS misses by $0.04

BeyondSpring Announces Final Positive Data from the PROTECTIVE-1 Phase 3 CIN Program of Plinabulin as a Single Agent Compared to Pegfilgrastim at the American Society of Clinical Oncology (ASCO) Annual Meeting

BeyondSpring reports positive plinabulin combo data for prevention of chemotherapy-induced neutropenia

BeyondSpring Announces First Patient Dosed in a Triple Combination Study with Plinabulin, PD-1/PD-L1 Inhibitor and Radiotherapy for the Reversal of Resistance to PD-1/PD-L1 Inhibitors in Patients with Advanced Solid Tumors

BeyondSpring Inc. Announces U.S. FDA Acceptance and Priority Review of New Drug Application for Plinabulin and G-CSF Combination for the Prevention of Chemotherapy-Induced Neutropenia

FDA grants accelerated review to BeyondSpring's plinabulin combo application; shares up 8%

BeyondSpring EPS misses by $0.17

BeyondSpring Announces Five Presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting

Chief Scientific Officer has left the company

BeyondSpring Inc. Announces Management Changes

Price target lowered to US$36.00

How Much Of BeyondSpring Inc. (NASDAQ:BYSI) Do Insiders Own?